Get the Stockscreener App
34.72
0.52%
0.18
After Hours:
34.40
-0.32
-0.92%
Capricor Therapeutics Inc stock is traded at $34.72, with a volume of 949.26K.
It is up +0.52% in the last 24 hours and up +13.84% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$34.54
Open:
$34
24h Volume:
949.26K
Relative Volume:
0.73
Market Cap:
$2.00B
Revenue:
$11.13M
Net Income/Loss:
$-105.04M
P/E Ratio:
-15.39
EPS:
-2.2565
Net Cash Flow:
$-81.54M
1W Performance:
+8.60%
1M Performance:
+13.84%
6M Performance:
+418.21%
1Y Performance:
+269.36%
1-Day Range:
$33.32
$34.77
1-Week Range:
$29.58
$35.99
52-Week Range:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
34.72 | 1.79B | 11.13M | -105.04M | -81.54M | -2.2565 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor's Former Executive Considered for FDA Biologics Chief - Intellectia AI
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics stock jumps as FDA resumes Deramiocel review - MSN
Q3 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
[ARS] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan
Capricor Therapeutics (NASDAQ: CAPR) details 2026 meeting, board elections, pay and Deramiocel deals - Stock Titan
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance - MSN
Aug Update: Is Capricor Therapeutics Inc stock a value trapMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
CAPR Should I Buy - Intellectia AI
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - The Chronicle-Journal
JPMorgan Chase Reduces Stake in Capricor Therapeutics - National Today
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
CAPR Forecast, Price Target & Analyst Ratings | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Aug PreEarnings: Whats the profit margin of Capricor Therapeutics IncQuarterly Profit Summary & Consistent Income Trade Ideas - baoquankhu1.vn
Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones - Stock Traders Daily
Capricor Therapeutics (CAPR) Is Up 7.2% After HOPE-3 Data And PDUFA Update Has The Bull Case Changed? - Sahm
Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone - Sahm
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock - marketbeat.com
Capricor Therapeutics (CAPR) director sells 7,529 exercised shares - Stock Titan
Option exercise and 10b5-1 sales reported by CAPR (NASDAQ: CAPR) - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6%Here's Why - MarketBeat
Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock - marketbeat.com
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock - marketbeat.com
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 25,000 Shares of Stock - MarketBeat
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Capricor Therapeutics(CAPR.US) Director Sells US$3.52 Million in Common Stock - Moomoo
Capricor Therapeutics EVP Krasney sells $752k in shares By Investing.com - Investing.com Canada
Capricor Therapeutics director sells $3.5m in shares - Investing.com UK
Capricor Therapeutics director sells $3.5m in shares By Investing.com - Investing.com Australia
Capricor (NASDAQ: CAPR) EVP sells 25K shares after option exercises - Stock Titan
Director at Capricor (NASDAQ: CAPR) sells 115,000 shares via 10b5-1 plan - Stock Titan
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - MSN
Capricor Therapeutics (NASDAQ: CAPR) proxy: Board nominees, pay and Nippon Shinyaku deals - Stock Titan
[144] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan
Capricor Therapeutics Stock Rises Above 50-Day Average - National Today
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Insider Sell: Is Capricor Therapeutics Inc stock a good dividend stock2026 Price Momentum & Safe Capital Preservation Plans - baoquankhu1.vn
Value Recap: Is Capricor Therapeutics Inc a defensive stock2026 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn
Is Capricor Therapeutics Inc stock a good dividend stock2026 Retail Activity & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Capricor (CAPR) EVP and General Counsel exercises options for 2,500 shares - stocktitan.net
Bull Run: Does Capricor Therapeutics Inc stock benefit from AI growth2026 Support & Resistance & Real-Time Sentiment Analysis - baoquankhu1.vn
Momentum Shift: Is AKAM a top pick in the sectorTreasury Yields & Comprehensive Market Scan Reports - baoquankhu1.vn
Merger Talk: How does Capricor Therapeutics Inc perform in inflationary periods2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Technical Reactions to CAPR Trends in Macro Strategies - Stock Traders Daily
CAPR Technical Analysis | Trend, Signals & Chart Patterns | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor Therapeutics Tokenized Stock (Ondo) price today, CAPRon to USD live price, marketcap and chart - CoinMarketCap
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):